Please login to the form below

Not currently logged in
Email:
Password:

psoriatic arthritis

This page shows the latest psoriatic arthritis news and features for those working in and with pharma, biotech and healthcare.

Novartis gains label boost for Cosentyx

Novartis gains label boost for Cosentyx

Cosentyx has been in the psoriatic arthritis (PsA) market for almost four years now, and has also established itself in plaque psoriasis and ankylosing spondylitis. ... The lack of long-term efficacy for psoriatic arthritis treatments causes patients to

Latest news

More from news
Approximately 13 fully matching, plus 101 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Boehringer Ingelheim) for psoriatic arthritis, Crohn’s disease and other inflammatory conditions. ... AbbVie has five trials on the go in rheumatoid arthritis and will be filing in that indication before the end of the year.

  • The good, the bad and the ugly The good, the bad and the ugly

    Elsewhere, Celgene has seen large growth in 2017 (46%) - driven by sales of Otezla, the first oral small molecule to be approved for psoriasis and psoriatic arthritis. ... Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic

  • Deal Watch December 2016 Deal Watch December 2016

    510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... The Scandinavian company, Nuevolution, uses its drug discovery platform Chemetics to discover novel small

  • Taking a strategic approach Taking a strategic approach

    Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of

  • Pharma deals during July 2014 Pharma deals during July 2014

    Cimzia, a pegylated antibody fragment that blocks tumour necrosis factor alpha, is currently indicated for several disorders including Crohn's disease, rheumatoid arthritis and psoriatic arthritis. Based on promising phase 2

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics